Figure 4.

Comparison of placebo‐adjusted treatment effect (model predicted) for systemic psoriasis treatments: landmark analysis. Point estimates and 90% confidence intervals are predicted from model simulations (N = 1,000) for each drug, assuming a typical body weight of 90 kg. The recommended dosage for ustekinumab is based on body weight (45 mg ustekinumab for ≤ 100 kg or 90 mg ustekinumab for > 100 kg). Therefore, the simulation (N = 500 for each body weight strata) for ustekinumab was conducted by body weight ≤100 kg and >100 kg, in which different doses (45 mg or 90 mg) were assigned before calculating ustekinumab weighted average PASI responses. b.i.d., twice daily; b.i.w., twice weekly; CI, confidence interval; PASI50/75/90/100, ≥ 50%, ≥ 75%, ≥ 90%, or 100% reduction from baseline Psoriasis Area and Severity Index score; q.d., once daily; q.w., once weekly; q2w, once every 2 weeks; q4w, once every 4 weeks; q8w, once every 8 weeks; q12w, once every 12 weeks. [Color figure can be viewed at cpt-journal.com]